Changes in inner retinal layer thickness in patients with exudative age-related macular degeneration during treatment with anti-vascular endothelial growth factor

• Published in: Medicine (Baltimore) Vol. 99; no. 17; p. e19955
• Main Authors: Lee, Seong Woo, Sim, Ha Eun, Park, Jae Yong, Kim, Jae Suk, Chang, In Beom, Park, Young Soon, Hwang, Je Hyung
• Format: Journal Article
• Language: English
• Published: United States Wolters Kluwer Health 01.04.2020
• Subjects: Aged; Aged, 80 and over; Angiogenesis Inhibitors - pharmacology; Angiogenesis Inhibitors - therapeutic use; Female; Humans; Macular Degeneration - drug therapy; Male; Middle Aged; Observational Study; Ranibizumab - pharmacology; Ranibizumab - therapeutic use; Receptors, Vascular Endothelial Growth Factor - therapeutic use; Recombinant Fusion Proteins - pharmacology; Recombinant Fusion Proteins - therapeutic use; Retina - pathology; Retina - physiopathology; Retrospective Studies; Statistics, Nonparametric; Vascular Endothelial Growth Factors - pharmacology; Vascular Endothelial Growth Factors - therapeutic use; Weights and Measures
• ISSN: 0025-7974; 1536-5964
• DOI: 10.1097/MD.0000000000019955

The aim of this study was to identify any changes that occur in the retinal nerve fiber layer (RNFL) and ganglion cell-inner plexiform layer (GC-IPL) in patients with exudative age-related macular degeneration (AMD) during treatment with anti-vascular endothelial growth factor (VEGF) injections.Patients were enrolled in this retrospective study if they had exudative AMD, had received at least 3 injections of ranibizumab or aflibercept, and had a minimum of 12 months of follow-up. We analyzed the changes in the RNFL and GC-IPL using spectral-domain optical coherence tomography in rescan mode.Fifty-two eyes of 52 patients who had been treated with repeated anti-VEGF injections for exudative AMD were included. At the final visit, there was no significant between-group difference in best-corrected visual acuity or intraocular pressure. There was a significant decrease in central macular thickness in all groups (P < .05). There was a decrease in RNFL thickness that was only statistically significant in the ranibizumab group and when the ranibizumab or aflibercept groups were combined (P = .036 and .044, respectively). The thickness of the GC-IPL layer was significantly decreased in the aflibercept and total group (P = .035 and P = .048, respectively).The thicknesses of the RNFL and GC-IPL decreased in patients with exudative AMD who underwent repeated anti-VEGF injections.